Science Explorer Back to mapMap
Institution · Eli Lilly (Spain)

Most cited papers from Eli Lilly (Spain)

What are the most cited papers from Eli Lilly (Spain)?

The most cited paper from Eli Lilly (Spain) is "The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2" (George W. Sledge, Masakazu Toi, Patrick Neven et al., 2019), with 1,016 citations. Next come "Adherence to Therapies in Patients with Type 2 Diabetes" (744) and "MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer" (693).

Showing 50 of 61 papers. Every paper with more than 87 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2 George W. Sledge, Masakazu Toi, Patrick Neven et al. · JAMA Oncology Open access 29 Sep 2019 1,016
2 Adherence to Therapies in Patients with Type 2 Diabetes Luis‐Emilio García‐Pérez, María Daca-Álvarez, Tatiana Dilla et al. · Diabetes Therapy Open access 29 Aug 2013 744
3 MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer Stephen R.D. Johnston, Miguel Martín, Angelo Di Leo et al. · npj Breast Cancer Open access 11 Jan 2019 693
4 Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial Bernhard H. Ludvik, Francesco Giorgino, Esteban Jódar et al. · The Lancet Aug 2021 628
5 Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial David L. Kendler, Fernando Marín, Cristiano A. F. Zerbini et al. · The Lancet Open access 9 Nov 2017 599
6 The Evolution of High-Throughput Experimentation in Pharmaceutical Development and Perspectives on the Future Steven M. Mennen et al. · Organic Process Research & Development Open access 7 May 2019 589
7 Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine Lawrence M. Gelbert, Shufen Cai, Xi Lin et al. · Investigational New Drugs Open access 11 Jun 2014 576
8 Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial Amalia Gastaldelli, Kenneth J. Cusi, Laura Fernández Landó et al. · The Lancet Diabetes & Endocrinology 22 Apr 2022 500
9 Patient involvement in clinical research: why, when, and how José Antonio Sacristán, Alfonso Aguarón, C. Avendaño et al. · Patient Preference and Adherence Open access Apr 2016 382
10 Problems and solutions in calculating quality-adjusted life years (QALYs). Luis Manuel Prieto, José Antonio Sacristán · Health and Quality of Life Outcomes Open access 2003 378
11 ¿Qué es una tecnología sanitaria eficiente en España? José Antonio Sacristán, Juan Oliva, J. del Llano et al. · Gaceta Sanitaria Open access 2002 361
12 Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors Moritz Schütte et al. · Nature Communications Open access 10 Feb 2017 357
13 Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment Víctor Pérez, Inmaculada Gilaberte, Douglas E. Faries et al. · The Lancet May 1997 302
14 Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft Thomas J. Raub, Graham N. Wishart, Palaniappan Kulanthaivel et al. · Drug Metabolism and Disposition 6 Jul 2015 288
15 Patient-centered medicine and patient-oriented research: improving health outcomes for individual patients José Antonio Sacristán · BMC Medical Informatics and Decision Making Open access 8 Jan 2013 282
16 2-Amino-3-substituted-6-[(E)-1-phenyl-2-(N-methylcarbamoyl)vinyl]imidazo[1,2-a]pyridines as a Novel Class of Inhibitors of Human Rhinovirus: Stereospecific Synthesis and Antiviral Activity Chafiq Hamdouchi, Jesús de Blas, Mirian del Prado et al. · Journal of Medicinal Chemistry 22 Dec 1998 280
17 Underdiagnosis of Attention-Deficit/Hyperactivity Disorder in Adult Patients Ylva Ginsberg, Javier Quintero, Ernie Anand et al. · The Primary Care Companion For CNS Disorders Open access 12 Jun 2014 275
18 Classical Test Theory versus Rasch analysis for quality of life questionnaire reduction. Luis Manuel Prieto, Jordi Alonso, Rosa Lamarca · Health and Quality of Life Outcomes Open access 2003 263
19 Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib Xueqian Gong et al. · Cancer Cell Open access Dec 2017 243
20 Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the RB1 Tumor Suppressor Gene Xueqian Gong et al. · Cancer Discovery 29 Oct 2018 239
21 Cyclin dependent kinase (CDK) inhibitors as anticancer drugs Concepción Sánchez‐Martínez, Lawrence M. Gelbert, Marı́a José Lallena et al. · Bioorganic & Medicinal Chemistry Letters Open access 6 Jun 2015 238
22 Targeting the Synapse in Alzheimer’s Disease Johanna Jackson, Enrique Jambrina, Jennifer Li et al. · Frontiers in Neuroscience Open access 23 Jul 2019 229
23 Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2− Breast Cancer Sara A. Hurvitz, Miguel Martín, Michael F. Press et al. · Clinical Cancer Research Open access 15 Oct 2019 227
24 Metallaphotoredox-Catalyzed Cross-Electrophile C sp 3 –C sp 3 Coupling of Aliphatic Bromides Russell T. Smith, Xiaheng Zhang, Juan A. Rincón et al. · Journal of the American Chemical Society Open access 5 Dec 2018 225
25 Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015–2019) Concepción Sánchez‐Martínez, Marı́a José Lallena, Sonia Gutiérrez Sanfeliciano et al. · Bioorganic & Medicinal Chemistry Letters Open access 26 Aug 2019 212
26 Preclinical characterization of abemaciclib in hormone receptor positive breast cancer Raquel Torres-Guzmán, Bruna Calsina, Ana Hermoso et al. · Oncotarget Open access 10 May 2017 202
27 Worse Quality of Life for Children With Newly Diagnosed Attention-Deficit/Hyperactivity Disorder, Compared With Asthmatic and Healthy Children Rodrigo Renda de Escobar, César A. Soutullo, Amaia Hervás et al. · PEDIATRICS Sep 2005 189
28 Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial Miguel Martín, Amparo Ruı́z, Monserrat Muñoz et al. · The Lancet Oncology 17 Feb 2007 187
29 Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3 Hope S. Rugo, Jens Huober, José Á. García-Sáenz et al. · The Oncologist Open access 21 Sep 2020 182
30 Cross-national clinical and functional remission rates: Worldwide Schizophrenia Outpatient Health Outcomes (W-SOHO) study Josep María Haro, Diego Novick, Jordan Bertsch et al. · The British Journal of Psychiatry Open access Sep 2011 178
31 A Randomized Double-Blind Study of Atomoxetine Versus Placebo for Attention-Deficit/Hyperactivity Disorder Symptoms in Children With Autism Spectrum Disorder Myriam Harfterkamp, Gigi van de Loo-Neus, Ruud B. Minderaa et al. · Journal of the American Academy of Child & Adolescent Psychiatry Open access 25 May 2012 172
32 Assay Establishment and Validation of a High-Throughput Screening Platform for Three-Dimensional Patient-Derived Colon Cancer Organoid Cultures Karsten Boehnke, Philip W. Iversen, Dirk Schumacher et al. · SLAS DISCOVERY Open access 27 May 2016 152
33 Elderly Patients Benefit From Second-Line Cytotoxic Chemotherapy: A Subset Analysis of a Randomized Phase III Trial of Pemetrexed Compared With Docetaxel in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer Glen J. Weiss, Corey Jay Langer, Rafael Rosell et al. · Journal of Clinical Oncology Open access 18 Sep 2006 148
34 Validation of the Excited Component of the Positive and Negative Syndrome Scale (PANSS-EC) in a naturalistic sample of 278 patients with acute psychosis and agitation in a psychiatric emergency room Alonso G. Montoya, Amparo Valladares, Luís Lizán et al. · Health and Quality of Life Outcomes Open access 2011 141
35 Twice‐daily pre‐mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with Type 2 diabetes James K. Malone, Shuang Bai, Barbara N. Campaigne et al. · Diabetic Medicine 21 Mar 2005 140
36 Is psychoeducation for parents and teachers of children and adolescents with ADHD efficacious? A systematic literature review Alonso G. Montoya, Francesc Colom, Meredith Ferrin · European Psychiatry Review 3 Feb 2011 137
37 Major depressive disorder in Latin America: The relationship between depression severity, painful somatic symptoms, and quality of life RODRIGO A. MUNOZ, Margaret E. McBride, Alan J. M. Brnabic et al. · Journal of Affective Disorders 3 Mar 2005 131
38 Symptomatic remission and social/vocational functioning in outpatients with schizophrenia: Prevalence and associations in a cross-sectional study Luis San, Antonio Ciudad, Enric Álvarez et al. · European Psychiatry 2 Oct 2007 128
39 Structural determinants of dual incretin receptor agonism by tirzepatide Bingfa Sun et al. · Proceedings of the National Academy of Sciences Open access 25 Mar 2022 127
40 Acromegaly Quality of Life Questionnaire (AcroQoL). Xavier Costa Badia, Susan M. Webb, Luís Prieto et al. · Health and Quality of Life Outcomes Open access 2004 127
41 Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity Robert M. Campbell et al. · Molecular Cancer Therapeutics 19 Dec 2013 124
42 Adherencia y persistencia terapéutica: causas, consecuencias y estrategias de mejora Tatiana Dilla, Amparo Valladares, Luís Lizán et al. · Atención Primaria Open access Jun 2009 120
43 Selection of heterocycles for drug design Howard B. Broughton, Ian A. Watson · Journal of Molecular Graphics and Modelling 12 May 2004 119
44 Imidazolyl benzimidazoles and imidazo[4,5-b]pyridines as potent p38α MAP kinase inhibitors with excellent in vivo antiinflammatory properties Mary M. Mader et al. · Bioorganic & Medicinal Chemistry Letters Open access 14 Nov 2007 117
45 Effects of Teriparatide Compared with Risedronate on the Risk of Fractures in Subgroups of Postmenopausal Women with Severe Osteoporosis: The VERO Trial Piet Geusens, Fernando Marín, David L. Kendler et al. · Journal of Bone and Mineral Research Open access 12 Jan 2018 115
46 Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: An open-label, prospective, nonrandomized, observational study Carmen Turbí, Gabriel Herrero‐Beaumont, J.C. Acebes et al. · Clinical Therapeutics Feb 2004 108
47 Factor analysis of the Zung self-rating depression scale in a large sample of patients with major depressive disorder in primary care Irene Romera, Helena Delgado-Cohen, Teresa Pérez et al. · BMC Psychiatry Open access 14 Jan 2008 107
48 Raloxifene: Mechanism of Action, Effects on Bone Tissue, and Applicability in Clinical Traumatology Practice José Ramón Caeiro Rey, Eduardo Vaquero Cervino, María Luz Rentero et al. · The Open Orthopaedics Journal Open access 20 Feb 2009 104
49 A Novel CDK9 Inhibitor Shows Potent Antitumor Efficacy in Preclinical Hematologic Tumor Models Tinggui Yin et al. · Molecular Cancer Therapeutics Open access Apr 2014 104
50 Prevalencia del síndrome metabólico (criterios del ATP-III). Estudio de base poblacional en áreas rural y urbana de la provincia de Segovia Nicholas G. Martin, Cristina Fernández, José Luis González‐Sánchez et al. · Medicina Clínica Oct 2005 102

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.